Efficacy of nimodipine use in ischemic stroke
DOI:
https://doi.org/10.29076/issn.2602-8360vol9iss16.2025pp108-114pKeywords:
ischemic stroke, nimodipine, neuronal damageAbstract
Ischemic stroke (IS) is one of the leading causes of disability worldwide. Nimodipine, a calcium channel blocker, has been extensively investigated as a potential neuroprotective agent. However, its efficacy in ischemic stroke remains controversial. This study aimed to evaluate the efficacy of nimodipine in reducing ischemic lesion size and improving functional outcomes in patients with acute ischemic stroke. The study follows a descriptive, longitudinal, and retrospective design based on a positivist paradigm. A systematic review of articles from PubMed, the Cochrane Library, Scopus, and Google Scholar was conducted, focusing on studies that assessed the effectiveness of nimodipine in ischemic stroke. Results revealed conflicting findings due to the drug’s side effects, timing, method of administration, and dosage, with most clinical trials yielding negative outcomes. These findings underscore the need for a more thorough evaluation of nimodipine administration, as well as additional clinical trials in different patient subgroups. In conclusion, although nimodipine has shown potential in improving cerebral perfusion and reducing ischemic neuronal damage, there is insufficient concrete evidence to clearly support the benefit of using this calcium channel blocker in ischemic stroke. Further research is recommended to clarify its efficacy, as the current scientific literature on the subject is limited. Additional studies are needed to confirm these findings and explore the underlying mechanisms of nimodipine's effects in ischemic stroke.
Downloads
References
1. Clinical trial of nimodipine in acute ischemic stroke. The American Nimodipine Study Group. Stroke. 1992;23(1):3–8.
2. Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ (Buddy), Culebras A, et al. An Updated Definition of Stroke for the 21st Century. Stroke. 2013;44(7):2064–89.
3. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35–41.
4. Markus HS, de Leeuw FE. Cerebral small vessel disease: Recent advances and future directions. International Journal of Stroke. 2023;18(1):4–14.
5. Hoh BL, Ko NU, Amin-Hanjani S, Chou SHY, Cruz-Flores S, Dangayach NS, et al. 2023 Guideline for the Management of Patients With Aneurysmal Subarachnoid Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2023;54(7).
6. Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. New England Journal of Medicine. 2018;378(1):11–21.
7. Widimsky P, Snyder K, Sulzenko J, Hopkins LN, Stetkarova I. Acute ischaemic stroke: recent advances in reperfusion treatment. Eur Heart J. 2023;44(14):1205–15.
8. Hoh BL, Ko NU, Amin-Hanjani S, Chou SHY, Cruz-Flores S, Dangayach NS, et al. 2023 Guideline for the Management of Patients With Aneurysmal Subarachnoid Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2023;54(7).
9. Zamponi GW, Striessnig J, Koschak A, Dolphin AC. The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential. Pharmacol Rev. 2015;67(4):821–70.
10. Bean BP. Nitrendipine block of cardiac calcium channels: high-affinity binding to the inactivated state. Proceedings of the National Academy of Sciences. 1984;81(20):6388–92.
11. Tang L, Gamal El-Din TM, Swanson TM, Pryde DC, Scheuer T, Zheng N, et al. Structural basis for inhibition of a voltage-gated Ca2+ channel by Ca2+ antagonist drugs. Nature. 2016;537(7618):117–21.
12. Zuccotti A, Clementi S, Reinbothe T, Torrente A, Vandael DH, Pirone A. Structural and functional differences between L-type calcium channels: crucial issues for future selective targeting. Trends Pharmacol Sci. 2011;32(6):366–75.
13. Kisler K, Nelson AR, Montagne A, Zlokovic BV. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat Rev Neurosci. 2017;18(7):419–34.
14. Murphy SJX, Werring DJ. Stroke: causes and clinical features. Medicine. 2020;48(9):561–6.
15. Maida CD, Norrito RL, Daidone M, Tuttolomondo A, Pinto A. Neuroinflammatory Mechanisms in Ischemic Stroke: Focus on Cardioembolic Stroke, Background, and Therapeutic Approaches. Int J Mol Sci. 2020;21(18):6454.
16. Tomassoni D, Lanari A, Silvestrelli G, Traini E, Amenta F. Nimodipine and Its Use in Cerebrovascular Disease: Evidence from Recent Preclinical and Controlled Clinical Studies. Clin Exp Hypertens. 2008;30(8):744–66.
17. Tomassoni D, Lanari A, Silvestrelli G, Traini E, Amenta F. Nimodipine and Its Use in Cerebrovascular Disease: Evidence from Recent Preclinical and Controlled Clinical Studies. Clin Exp Hypertens. 2008;30(8):744–66.
18. Hennerici M, Krämer G, North PM, Schmitz H, Tettenborn D. Nimodipine in the Treatment of Acute MCA Ischemic Stroke I. Cerebrovascular Diseases. 1994;4(3):189–93.
19. Zhang J, Yang J, Zhang C, Jiang X, Zhou H, Liu M. Calcium antagonists for acute ischemic stroke. Cochrane Database of Systematic Reviews. 2019;2(2):CD001928. doi: 10.1002/14651858.CD001928.pub3
20. Bogousslavsky J, Regli F, Zumstein V, Köbberling W. Double-Blind Study of Nimodipine in Non-Severe Stroke. Eur Neurol. 1990;30(1):23–6.
21. Trust Study Group. Randomised, double-blind, placebo-controlled trial of nimodipine in acute stroke. The Lancet. 1990;336(8725):1205–9.
22. Ahmed N, Näsman P, Wahlgren NG. Effect of Intravenous Nimodipine on Blood Pressure and Outcome After Acute Stroke. Stroke. 2000;31(6):1250–5.
23. Lei G, Rao Z, Hu Y. The efficacy of different nimodipine administration route for treating subarachnoid hemorrhage: A network meta-analysis. Medicine. 2023;102(39):e34789.
24. Tomassoni D, Lanari A, Silvestrelli G, Traini E, Amenta F. Nimodipine and Its Use in Cerebrovascular Disease: Evidence from Recent Preclinical and Controlled Clinical Studies. Clin Exp Hypertens. 2008;30(8):744–66.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 FACSALUD-UNEMI
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Todos los artículos de la Revista FACSalud UNEMI son difundidos bajo licencia internacional Creative Commons Reconocimiento-NoComercial-SinObrasDerivadas 4.0.
Los autores mantienen los derechos de autor, y, por lo tanto, son libres de compartir, copiar, distribuir, ejecutar y comunicar públicamente la obra bajo las condiciones siguientes: Reconocer los créditos de la obra especificada por el autor e indicar si se realizaron cambios (puede hacerlo de cualquier forma razonable, pero no de una manera que sugiera que el autor respalda el uso que hace de su obra. No utilizar la obra para fines comerciales. En caso de remezcla, transformación o desarrollo, no puede distribuirse el material modificado.
